MIST Milestone Pharmaceuticals Inc

$MIST Medicaid coverage of Cardamyst is expanding steadily and quietly. Medicaid accounts for 10% of the total PSVT patients (Commercial 45%, Medicare 45%) and normally it pays little but PA hurdles tend to be higher than commercial plans. Based on my own DD, more than half of total Medicaid lives are covered already and CA and TX are the key states to complete Medicaid coverage. Attached the Medicaid coverage map for your reference. Hope your generous understanding if there's any mistake.

$MIST Almost half of PSVT patients are 65+ and eligible for Medicare. We can check the 2027 Medicare formularies within a few days, and some early signals make me expect a better than par result. Some Medicare employer plan payers (SilverScript and Humana) have disclosed that Cardamyst will be covered in 2027. Several downstream EGWPs that adopt those formularies have also published their 2027 drug lists based on the upstream formulary. So far, plans such as Delaware, CalPERS, and the NC retiree Medicare plan have decided to cover Cardamyst in 2027 under favorable conditions, and there are many other EGWPs that used the same formulary IDs as those plans in 2026. They are highly likely to adopt the same 2027 formularies and cover Cardamyst as well. Yes, all of the clues I mentioned are from employer plans, which are different from individual Medicare plans. Nevertheless, it's a positive signal that the company has taken a good step forward in gaining access to the Medicare system.

$MIST Recently, I've noticed that postings about getting and using Cardamyst seem to be appearing more frequently in the largest FB PSVT patient communities. The stories follow a similar pattern - it worked well, some nasal and throat discomfort, confusion about how to use the spray, and wanting to get a refill.

$MIST another patient post, worked within minutes with only one spray in one nostril. It will be the standard of care-just a matter of time.

$MIST When the Committee for Medicinal Products for Human Use (CHMP) issues a positive opinion for a drug (this week), it means the committee has scientifically concluded that the medicine meets required standards for quality, safety, and efficacy, and that its benefits outweigh its risks. The CHMP formally transmits its positive scientific recommendation and assessment report to the European Commission (EC). The EMA publishes a summary of the opinion on its website (typically on the Friday following the CHMP plenary meeting). Within 67 days of receiving the CHMP's positive opinion, the European Commission typically issues an official Implementing Decision to grant a centralized marketing authorization. Once the European Commission adopts the decision, the marketing authorization becomes legally valid across all 27 EU member states, as well as Iceland, Liechtenstein, and Norway (the European Economic Area / EEA).

$MIST Decision is made these days for EU approval. “Following guidance from the EMA, this MAA incorporates the global clinical data package that supported the U.S. Food and Drug Administration approval of etripamil for the treatment of PSVT,” said Joseph Oliveto, President and Chief Executive Officer of Milestone Pharmaceuticals. “TACHYMIST could become the first approved patient self-administered therapy representing a meaningful step forward in patient care for the approximately two million people suffering from PSVT in Europe.”

$MIST good morning $MISTers. Let's have a strong finish to the week and start off Q4 with some big green wood on that chart?💚

$MIST Another successful CARDAMYST experience posted today, kicked in within 7mins, helping the patient avoid an ER visit. I have strong conviction in this drug. If the product delivers, word spread, sales will eventually follow.

$MIST FRF files for medicaid, no frf no coverage. not saying this is a gimme but we should see more formulary adds in the next few months than weve already seen. if you type out ”Cardamyst” filetype:pdf and say past month you will see lots of adds tier 3 higher lower whatever. i have not seen step therapy or crazy QL so far GLTA

$MIST We’ve now reached ~400 Cardamyst prescriptions per week. If weekly prescriptions grow at a much more conservative pace of around 2.5% per week, Cardamyst could reach roughly 1,900–2,000 prescriptions per week by the end of 2027, equivalent to an annualized run rate of around 100,000 prescriptions. And remember, insurance coverage is still only around 50%, while Medicare access is expected to ramp gradually starting in Q4. A significant portion of the SVT population is 65+ and Medicare-eligible, leaving substantial room for improved access and continued prescription growth. The future looks very promising, and the investment case remains highly attractive—but patience is the key to success.

$MIST I'm going to test my reverse psychology theory. This POS is ALWAYS red. There's no hope. It's going to RS then go OTC. Let's all get out while we still can!

$MIST - H.C. Wainwright analyst maintained $8 price target on 9/22/2026. We also have 2 (5) start analyst from TD Cowen and Wells Fargo that have an $8.00 and $7.00 price target as of August 13th. Let's hope they are more right than wrong. Keep in mind the revenue forecast is $1.14 Million to 1.17 Million. And we know that we already have $2 Million in the bag with the China revenue plus we had $1.034 Million in deferred revenue on the balance sheet. Maybe we see $1.5 Million in product revenue for Q3. It will be interesting to see if they have sold any product to Everest Medicines as an initial build for the China inventory, or if they can shed some light on how the China ramp is going.

$MIST In EU, Cardamyst is now "ready for adoption" in the next agency meeting Oct 12 - Oct 15, this means just now. In drug regulatory affairs —most notably within the European Medicines Agency (EMA) and its scientific committees like the CHMP and PRAC—"Action: For adoption" indicates that a specific item or document is ready for official approval, finalization, or endorsement by the committee. When a document's status or required action is marked as "For adoption" on a committee agenda, it means: • The Review Phase is Complete: The preliminary scientific evaluation, drafting, and revisions of the document have already taken place. • Ready for Vote or Consensus: The committee is being asked to formally accept and sign off on the text during that meeting. • Transition to Final Status: Once adopted, the document changes from a "draft" to an official, binding output of the agency.

$MIST Anyone here that thinks this is going to zero is a daft brush. We may hit .59 but i dont see it going below that. If it does it will be a gift and afterwards a violent uptick will happen. PT is 1.80-2.20. Paytience is needed. No emotions in trading. I have been in this stonk since 2018. Made a lot of bank on this. Juice is worth the squeeze. This and $VSTM are very volatile and money making.

$MIST - Today will be the 17th straight trading day that falls below the $1.00 listing requirement. I know that this is concerning to many of the posters on this board. There are several reasons to believe Q3 reporting is expected on November 12th. The current analyst revenue projections are averaged at $1.14 Million to $1.17 Million with the lowest projection of $800,000 and a high projection of $2 Million. What do we know ahead of the report. Milestone showed $1.034 million in deferred revenue on Q2 report if all of that is realized in Q3 than the company should report around $1.5 million in regular revenue. We also know that there will be a $2 Million milestone payment from Everest Medicines for China Approval so now we are looking more like $3.5 Million in Revenue excluding and pre inventory build for China roll out. Then there is the European approval in early 2027 coming up and Milestone needs to get a distribution partner in place.

$MIST I bought some more. It’s 10th day below $1. But I do think this is more biotech sector related selling pressure than the individual stock of $MILESTONES. We should have moved up due to the good trial news from Canada. So I don’t blame the Company totally rather hope Joe learns to play the market a little better in PR release. You have to boost and market yourself if the street not recognizing you and your stock. Don’t get lazy and take for granted that somehow just because you have a FDA approved drug then all is good. I also agree that that top executives and Board members should buy 50-100 K shares in the open unless they have none public material news Btw during my buying in late hour in between $0.79-0.78 ranges I felt the MM was not really dumping per se because my BID were at 3000 -5000 shares per order and they didn’t dump on me but spread out in 100/200/300/500 multiple executions. Anyway the Marco market & record SI will play into day to day fluctuations. BL

$MIST Fuck me, nearly 10% today. That's bloody harsh even for mist. I'm getting my arse handed to me again today. Terrible week all around!

$MIST - of the 21 drugs Up for the Prix Galien award for Best Pharmaceutical Product of 2026 Gemini Pro ranked CARDAMYST in the top 5. Public Health & Acute Care Solutions 4. NUZOLVENCE (Innoviva): Approved in late 2025, this first-in-class single-dose oral antibiotic specifically targets uncomplicated urogenital gonorrhea. With Neisseria gonorrhoeae rapidly mutating to resist standard treatments, Nuzolvence addresses a critical, escalating global public health threat. 5. CARDAMYST (Milestone Pharmaceuticals): In the realm of acute cardiovascular interventions, shifting paroxysmal supraventricular tachycardia (PSVT) management from the emergency room to an at-home nasal spray removes massive friction from the healthcare system. It provides immediate patient autonomy and drastically reduces hospital admissions during sudden arrhythmic episodes.

$MIST forced fund selling under $1 last couple of days creates a unique opportunity. Cash on hand still $170 million Coverage doubled at the very end of last earnings. So you saw only 25% coverage on 16 weeks commercial launch. Fantastic position here. Gift

Interesting MIST angle after Novo’s Capital Markets Day Novo explicitly outlined a “disciplined bolt-on business development strategy” and wants to diversify its pipeline beyond diabetes/obesity, including cardiovascular disease. That’s potentially relevant to $MIST: FDA-approved CARDAMYST, China approval already secured, Europe pending, and a Phase 3 AFib-RVR program underway. Novo’s materials do not mention MIST specifically, so this is not evidence of a deal. But the strategic fit is worth watching—especially given MIST’s tiny valuation relative to Novo.